Funds raised through the offering will be used to buy back shares of common stock from shareholders in privately negotiated transactions.
The company said it will use the proceeds from the offering for general corporate and working capital purposes.
The firm said it intends to use net proceeds from the issuance of the notes for general corporate purposes.
The company said it will use the funds to develop antimicrobial therapeutics based on CRISPR-Cas3 technology.
The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.
The firm privately negotiated the exchange with current holders of convertible notes due 2017.
Quidel will use the net proceeds from the offering for working capital and other general corporate purposes.
PositiveID will issue $4 million in senior secured convertible promissory notes to institutional investor Dominion Capital, the firm announced today.
NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday that it successfully completed the previously announced repurchase of convertible notes due in 2026 and the issuance
NEW YORK (GenomeWeb News) – Affymetrix said after the close of the market on Monday that it has given notice of its intention to redeem all of its outstanding 3.50 percent senior convertible notes due 2038.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.